Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 324 participants.

Also called NCT06220032

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 324 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06220032
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Netherlands (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06220032. Randomized; no masking; primary purpose treatment. Start 2024-08-15 (actual); primary completion 2028-12-15 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma
Acronym
HO170DLBCL
Condition
DLBCL - Diffuse Large B Cell Lymphoma
Intervention (Drug)
Dexrazoxane
Intervention (Drug)
Rituximab
Intervention (Drug)
Cyclophosphamide
Intervention (Drug)
Doxorubicin
Intervention (Drug)
Vincristine
Intervention (Drug)
Prednisolone
Intervention (Drug)
Lenalidomide
Intervention (Drug)
Pegfilgrastim
Lead sponsor
Stichting Hemato-Oncologie voor Volwassenen Nederland (class: other)
Collaborator
UMC Utrecht (class: other)
Collaborator
Amsterdam UMC, location VUmc (class: other)
Collaborator
The Dutch Network for Cardiovascular Research (WCN) (class: not stated)

Record details

Record id
cardio:ct-nct06220032
Content hash
029f10f421a2e98ddf6f71f0d7000a4c00cb60210971cf273527ffcb0ab615e5